NEBCIN
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Jun 1975
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 9h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NEBCIN is an injectable small-molecule antibiotic approved in 1975 by Eli Lilly and Company. The specific mechanism of action and indications are not publicly detailed in available data, but its injectable formulation suggests use in serious infections. As a legacy product approaching loss of exclusivity, it represents a mature antimicrobial therapy.
LOE Approaching
As a legacy antibiotic nearing loss of exclusivity with moderate competitive pressure (30%), brand teams are likely focused on operational efficiency and managed decline rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on NEBCIN offers limited career growth potential given its LOE-approaching status and zero linked job opportunities. Roles focus on managing decline, defending market share, and operational efficiency rather than innovation or expansion.
Brand Manager (legacy products)Field Sales (hospital/institutional)
Worked on NEBCIN at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.